CTRI/2009/091/001052招募中1 期
An open-label, randomized, four-period, crossover study toassess the effect of SMC021 (0.8 mg recombinant salmoncalcitonin/200 mg 5-CNAC) on the pharmacokinetics ofibuprofen 600 mg and paracetamol 1G and the effects ofibuprofen and paracetamol on the pharmacokinetics ofSMC021 in healthy volunteers
ovartis Healthcare Pvt Ltd0 个研究点目标入组 56 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Healthy male and female subjects age 35 to 65 years of age included, and in good health
排除标准
- •Significant illness within 2 weeks prior to dosing, history of ECG abnormalities, chronic illness associated with changes in bone density, recent or recurrent history of acute or chronic bronchospastic disease, autonomic dysfunction, cancer, medical or sugical condition whicch might alter the ADME of drug, positive hep and HIV screen, and bleeding disorders
研究者
相似试验
已完成
4 期
A phase IV, randomized, open label, cross-over, intervention trial to investigate the effect of the switch of protease inhibitors to raltegravir on endothelial function, chronic inflammation, immune activation and HIV replication below 50 copies/mlNL-OMON39957niversitair Medisch Centrum Utrecht24
进行中（未招募）
不适用
RAltegravir Switch STudy: effects on Endothelial RecoveryEUCTR2011-003298-26-NLniversity Medical Center Utrecht24
已完成
不适用
A randomized, open-label, four-way cross-over, single dose study to compare the pharmacokinetics of monomethyl fumarate and other metabolites after administration of dimethyl fumarate as a delayed- and slow-release formulation of FP187 and Tecfidera® in healthy volunteers.10029305Multiple SclerosisNL-OMON42906Forward Pharma GmbH24
已完成
不适用
clinical trial to investigate pharmacokinetic interaction between HGP0904, HGP0608 and HGP1405Diseases of the circulatory systemKCT0001693Hanmi Pharm28
进行中（未招募）
不适用
A study to determine the blood concentration of AFQ056 drug after taking a single dose, for 2 pediatric formulations in fed or fasted adult subjectsEUCTR2011-000365-12-GBovartis Pharma Services AG